GLP-1减重药物：Ozempic、Wegovy全面解读

GLP-1 (glucagon-like peptide-1) receptor agonists represent the most significant advancement in obesity treatment in decades. These medications mimic a natural gut hormone that regulates appetite and blood sugar:

• Appetite suppression: GLP-1 acts on brain receptors in the hypothalamus to reduce hunger and increase satiety, leading to naturally reduced food intake of 20-30%
• Slowed gastric emptying: Food stays in the stomach longer, prolonging feelings of fullness after meals
• Improved insulin sensitivity: Originally developed for type 2 diabetes, these medications reduce insulin resistance and blood sugar spikes
• Reduced food reward: Emerging neuroimaging research suggests GLP-1 agonists decrease the brain's reward response to high-calorie foods

The currently available medications include:

• Semaglutide (Wegovy): FDA-approved for weight management at 2.4mg weekly injection. Also sold as Ozempic (1-2mg) for diabetes.
• Tirzepatide (Mounjaro/Zepbound): A dual GIP/GLP-1 agonist showing even greater weight loss in trials (up to 22.5% body weight).
• Liraglutide (Saxenda): An older GLP-1 agonist with more modest results (5-8% weight loss).

Clinical trial data provides a clear picture of expected outcomes:

• STEP 1 trial (NEJM, 2021): Semaglutide 2.4mg produced average weight loss of 14.9% (vs. 2.4% placebo) over 68 weeks in adults with obesity. One-third of participants lost 20%+ body weight.
• SURMOUNT-1 trial (NEJM, 2022): Tirzepatide at highest dose produced average 22.5% weight loss over 72 weeks — approaching bariatric surgery results.
• Cardiovascular benefits: The SELECT trial (2023) showed semaglutide reduced major cardiovascular events by 20% in people with obesity and established heart disease.

Important caveats:

• Weight regain: The STEP 1 extension study found participants regained two-thirds of lost weight within 1 year of stopping the medication
• Muscle loss: Approximately 25-40% of weight lost is lean mass (muscle), which is a concern for long-term metabolic health. Resistance training and adequate protein (1.6g+/kg) are essential adjuncts.

If you are prescribed a GLP-1 medication, use WAYJET's Prescription Analyzer to verify dosing guidelines and check for interactions with your other medications.

GLP-1 medications have a generally well-established safety profile, but side effects are common, especially during dose escalation:

• Gastrointestinal (most common): Nausea (40-44%), diarrhea (30%), vomiting (24%), constipation (24%). Usually mild-to-moderate and improve over 4-8 weeks.
• Gallbladder issues: Rapid weight loss increases gallstone risk. The STEP trials reported cholelithiasis in 2-3% of semaglutide users vs. 1% placebo.
• Pancreatitis: Rare (0.1-0.3%) but serious. Seek immediate care for severe abdominal pain.
• Thyroid C-cell tumors: Observed in rodent studies at high doses. Contraindicated in patients with personal or family history of medullary thyroid carcinoma (MTC) or MEN2 syndrome.

Who should NOT take GLP-1 medications:

• Personal/family history of medullary thyroid cancer or MEN2
• History of pancreatitis
• Pregnant or planning to become pregnant (stop at least 2 months before conception for semaglutide)
• History of severe gastrointestinal disease

Cost remains a significant barrier: without insurance, Wegovy costs approximately $1,300-1,600 per month. Coverage varies significantly by insurer and employer plan.